Nucleobindin-2 mediates TGF-β1-driven phenotypes in ZEB1-high uterine carcinosarcoma.

[1]  T. Brabletz,et al.  Dynamic EMT: a multi‐tool for tumor progression , 2021, The EMBO journal.

[2]  A. Ożyhar,et al.  The Multifaceted Nature of Nucleobindin-2 in Carcinogenesis , 2021, International journal of molecular sciences.

[3]  D. Ribatti,et al.  Epithelial-Mesenchymal Transition in Cancer: A Historical Overview , 2020, Translational oncology.

[4]  Raymond B. Runyan,et al.  Guidelines and definitions for research on epithelial–mesenchymal transition , 2020, Nature Reviews Molecular Cell Biology.

[5]  R. Tao,et al.  Nucleobindin-2 enhances the epithelial-mesenchymal transition in renal cell carcinoma , 2020, Oncology letters.

[6]  M. Saegusa,et al.  S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma , 2019, Laboratory Investigation.

[7]  Jun Liu,et al.  Nucleobindin-2 Promotes the Growth and Invasion of Glioblastoma. , 2019, Cancer biotherapy & radiopharmaceuticals.

[8]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[9]  Guang-Ming Liu,et al.  Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer , 2018, Disease markers.

[10]  P. Dessein,et al.  Nesfatin-1 and visfatin expression is associated with reduced atherosclerotic disease risk in patients with rheumatoid arthritis , 2018, Peptides.

[11]  M. Saegusa,et al.  A functional role of LEFTY during progesterone therapy for endometrial carcinoma , 2017, Cell Communication and Signaling.

[12]  Wenbin Liu,et al.  Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis , 2017, Journal of Cancer.

[13]  Tsugumichi Saito,et al.  High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[14]  B. Dai,et al.  High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients , 2016, Oncotarget.

[15]  Jaw-Yuan Wang,et al.  Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer , 2016, Oncotarget.

[16]  Takashi Suzuki,et al.  Nucleobindin 2 (NUCB2) in human endometrial carcinoma: a potent prognostic factor associated with cell proliferation and migration. , 2016, Endocrine journal.

[17]  M. Yao,et al.  Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK–Mediated Phosphorylation of Akt , 2015, Clinical Cancer Research.

[18]  Yuhuan Wang,et al.  Serum Nesfatin-1 is Reduced in Type 2 Diabetes Mellitus Patients with Peripheral Arterial Disease , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[19]  K. Bhat,et al.  TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion , 2014, Cell Death and Disease.

[20]  Liang Li,et al.  High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer , 2014, Tumor Biology.

[21]  H. Matsumoto,et al.  Efficient extraction of proteins from formalin-fixed paraffin-embedded tissues requires higher concentration of tris(hydroxymethyl)aminomethane , 2014, Clinical Proteomics.

[22]  Y. Taché,et al.  Role of NUCB2/Nesfatin-1 in the Hypothalamic Control of Energy Homeostasis , 2013, Hormone and Metabolic Research.

[23]  Robert A. Weinberg,et al.  Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.

[24]  F. Nomura,et al.  Enhanced recovery of lyophilized peptides in shotgun proteomics by using an LC‐ESI‐MS compatible surfactant , 2013, Proteomics.

[25]  Takashi Suzuki,et al.  Nucleobindin 2 in human breast carcinoma as a potent prognostic factor , 2012, Cancer science.

[26]  M. Tena-Sempere,et al.  Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. , 2010, Journal of molecular endocrinology.

[27]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[28]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[29]  R. Foisner,et al.  The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.

[30]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[31]  G. Berx,et al.  DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells , 2005, Oncogene.

[32]  Timothy J Mitchison,et al.  Dissecting Temporal and Spatial Control of Cytokinesis with a Myosin II Inhibitor , 2003, Science.

[33]  Eduard Batlle,et al.  Snail Induction of Epithelial to Mesenchymal Transition in Tumor Cells Is Accompanied by MUC1 Repression andZEB1 Expression* , 2002, The Journal of Biological Chemistry.

[34]  W. McCluggage,et al.  Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas , 2002, International Journal of Gynecologic Cancer.

[35]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[36]  W. McCluggage,et al.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? , 2002, Journal of clinical pathology.

[37]  A. G. Herreros,et al.  The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells , 2000, Nature Cell Biology.

[38]  Kenneth M. Yamada,et al.  The Zinc-Finger Protein Slug Causes Desmosome Dissociation, an Initial and Necessary Step for Growth Factor–induced Epithelial–Mesenchymal Transition , 1997, The Journal of cell biology.

[39]  S. Barsky,et al.  Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. , 1996, The American journal of surgical pathology.

[40]  N. Weiss,et al.  The epidemiology of sarcomas of the uterus. , 1986, Journal of the National Cancer Institute.

[41]  Y. Korkut,et al.  Nesfatin-1 and its effects on different systems. , 2015, Hippokratia.

[42]  M. Chorváth,et al.  [Uterine Sarcomas - a review]. , 2012, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[43]  Lucila Ohno-Machado,et al.  Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. , 2011, Cancer research.

[44]  H. Kuramoto,et al.  Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma. , 2004, European journal of gynaecological oncology.